Mirum Pharmaceuticals Evaluates Livmarli in Long-Term Study for Alagille Syndrome and PFIC
Mirum Pharmaceuticals is conducting a long-term study to assess the safety and efficacy of Livmarli in patients with Alagille syndrome and PFIC.
Therapeutic Area
Therapeutic area intelligence for Progressive Familial Intrahepatic Cholestasis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.